In order to achieve its vaccination objectives, the Minister of Health, Olivier Véran, announced the opening of 35 large vaccination centers or vaccinodromes. An announcement that comes at a time when mistrust of Covid vaccines, and particularly AstraZeneca, is picking up again.
The launch of 35 vaccinodromes
To reach the goal of one million vaccinations at the end of April 2021, the government has decided to step up the pace by opening in the coming weeks 35 large vaccination centers, also called vaccinodromes. These large ephemeral centers will make it possible to vaccinate more quickly at the rate of vaccine deliveries.
Tuesday, March 23, 2021, Emmanuel Macron announced that the vaccine strategy would again evolve since from Saturday March 27, 2021, vaccination would be open to over 70 years without a condition of comorbidity. He also said: “ I want us to organize things in a methodical way, go down by age groups “. Faced with these measures to speed up vaccination, the question arises of vaccine stocks: will they be sufficient?
The thorny question of the AstraZeneca vaccine
If the vaccines from Pfizer and Moderna are well received by the French and more generally by Europeans, this is not the case for the Swedish-British vaccine. AstraZeneca which is gradually losing its luster. The opinion study carried out by YouGov and published on Monday March 22, 2021 highlights that 61% of French people believe that the vaccine against the Covid AstraZeneca is not safe.
The death of a 24-year-old student from Nantes on Thursday, March 18, 2021, who had been vaccinated with the product shortly before, raises suspicion, although for the moment nothing formally links his death to the vaccination. Another cause for concern: the revelation of the American National Institute of Allergy and Infectious Diseases. The American regulator estimated Tuesday, March 23, 2021, that thehe AstraZeneca laboratory had used data “ obsolete “ resulting in an incomplete estimate of the actual efficacy of his vaccine.
Thus, a withdrawal of the AstraZeneca vaccine, already reserved for people aged 55 and over, could significantly slow down the French vaccination campaign.